RxDoctor Payments Data

Joel Williams, MD

Plastic and Reconstructive Surgery · Dalton, GANPI 1821072406

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 27.0% of the total.

$4,653in general payments, 2019–2025

Across 111 payments — averaging $41.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Musculoskeletal Transplant Foundation Inc.$1K
  • Galderma Laboratories, L.p.$689
  • Mentor Worldwide LLC$513
  • Bard Peripheral Vascular, Inc.$347
  • Motiva USA, LLC$176
  • plus $672 from 10 others

What the payments were for

  • Food & beverage$4,653100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,653 in reported general payments places this provider in the 65th percentile of 83 plastic and reconstructive surgery providers in Georgia.

See all plastic and reconstructive surgery providers in Georgia

Medicare billing

Part B allowed, 2024
$32,082
Medicare patients
55
Services billed
133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cephalexin14$49
Ondansetron OdtOndansetron16$36

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Dalton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →